Jed W. Fahey, Sc.D., is a nutritional biochemist and director of the Cullman Chemoprotection Center at Johns Hopkins with a background in plant physiology, human nutrition, and phytochemistry. His research primarily focuses on the bioavailability and biological effects of isothiocyanates, particularly sulforaphane and glucoraphanin derived from broccoli seeds and sprouts. His published work includes clinical and laboratory studies evaluating these compounds in the contexts of metabolic health, skin disorders, autism spectrum disorder, schizophrenia, and cancer.
Approximately 55% of the current global human population is colonized with Helicobacter pylori.
"and something like 55% of the world's population at the moment has Helicobacter in their systems." (said at 0:45:00)
Historical global prevalence estimates for Helicobacter pylori infection frequently cited figures above 50%, with a 2017 meta-analysis concluding that more than half of the world's population was infected. However, updated global meta-analyses demonstrate a continuing decline in prevalence over recent decades. Between 2015 and 2022, global prevalence fell to approximately 43.9% in adults and 35.1% in children and adolescents. Therefore, while a figure near 55% reflects historical data, current global prevalence is estimated to be lower, between roughly 35% and 44%.
Approximately 15% of patients treated with triple antibiotic therapy for Helicobacter pylori cannot tolerate it or do not achieve eradication.
"to treat it with so-called triple therapy: three separate antibiotics, and kill it so you can't find it anymore. An alternative—and I should say about 15% of people who are given that treatment either can't take it or it doesn't work." (said at 0:46:40)
The statement bundles two distinct assertions: the composition of triple therapy and its failure/intolerance rate.
1. Regimen composition: Standard triple therapy for Helicobacter pylori infection does not consist of three separate antibiotics. Rather, it comprises one proton-pump inhibitor (an acid-suppressing medication) and two antibiotics (typically amoxicillin and clarithromycin, or metronidazole).
2. Failure and intolerance rates: The claim that approximately 15% (or more) of patients fail eradication or experience intolerance is well-supported by systematic reviews and meta-analyses of randomized trials. Intention-to-treat eradication rates for standard triple therapy range from 75% to 82% (representing an eradication failure rate of 18% to 25%), while adverse event rates are reported at roughly 19.5% to 20.4%.
Bernard Cipolla conducted a clinical trial in France demonstrating a significant reduction in PSA trajectory in prostate cancer patients using the supplement Prostaphane.
"and Bernard Cipolla in France, using actually that supplement. Cipolla's study used—where he showed a dramatic reduction in the trajectory of PSA numbers, used—what's it called? Prostaphane." (said at 2:15:35)
Bernard Cipolla and colleagues conducted a double-blind, randomized, placebo-controlled multicenter clinical trial in France evaluating 60 mg/day of stabilized free sulforaphane (Prostaphane) in 78 men with biochemical recurrence following radical prostatectomy. Although the trial's prespecified primary endpoint (a decrease in log PSA slope) was not statistically met, secondary endpoints demonstrated a substantial slowing of PSA progression: the PSA doubling time was extended by 86% compared with placebo (28.9 months vs. 15.5 months), and the mean increase in PSA over 6 months was significantly smaller in the sulforaphane group (+0.099 ng/mL vs. +0.620 ng/mL, p = 0.0433).